Regaining the response to erythropoietin following azacitidine in chronic myelomonocytic leukemia previously evolved from refractory anemia.
作者信息
Niscola Pasquale, Tendas Andrea, Merola Roberta, Orlandi Giulia, Scaramucci Laura, de Fabritiis Paolo
机构信息
Hematology Unit, S. Eugenio Hospital Rome, Clinical Pathology, Regina Elena National Cancer Institute, Rome, Italy.
出版信息
Blood Res. 2015 Sep;50(3):181-2. doi: 10.5045/br.2015.50.3.181. Epub 2015 Sep 22.
Abstract
摘要
相似文献
1
Regaining the response to erythropoietin following azacitidine in chronic myelomonocytic leukemia previously evolved from refractory anemia.
Blood Res. 2015 Sep;50(3):181-2. doi: 10.5045/br.2015.50.3.181. Epub 2015 Sep 22.
2
[Acquired hemophilia A associated with chronic myelomonocytic leukemia successfully treated by rituximab and azacitidine].
Rev Med Interne. 2018 Aug;39(8):654-657. doi: 10.1016/j.revmed.2018.03.373. Epub 2018 Apr 10.
3
Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes.
Clin Cancer Res. 2005 May 15;11(10):3604-8. doi: 10.1158/1078-0432.CCR-04-2135.
4
Predictive Model for Infection Risk in Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Patients Treated With Azacitidine; Azacitidine Infection Risk Model: The Polish Adult Leukemia Group Study.
Clin Lymphoma Myeloma Leuk. 2019 May;19(5):264-274.e4. doi: 10.1016/j.clml.2019.01.002. Epub 2019 Jan 23.
5
[Effectiveness of azacitidine in chronic myelomonocytic leukemia harboring del(20q) - a case report].
Gan To Kagaku Ryoho. 2014 Jun;41(6):781-4.
6
[Transfusional independence in a patient with refractory anemia with excess blasts-2 refractory to 5-azacitidine treated with deferasirox and colony stimulating factors].
Med Clin (Barc). 2014 Jan 21;142(2):91-2. doi: 10.1016/j.medcli.2013.04.023. Epub 2013 Jun 20.
7
8
Response to erythropoietin in chronic myelomonocytic leukaemia.
Intern Med J. 2001 Aug;31(6):371-2. doi: 10.1046/j.1445-5994.2001.00074.x.
9
[Chronic myelomonocytic leukemia evolved from refractory anemia with excess of blasts, associated with karyotypic abnormality and marked monocytosis].
Rinsho Ketsueki. 1988 Nov;29(11):2145-51.
10
Chronic myelomonocytic leukemia following refractory anemia with sideroblasts: report of two cases.
Eur J Haematol. 1987 Feb;38(2):197-9. doi: 10.1111/j.1600-0609.1987.tb01161.x.
本文引用的文献
1
Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes.
Br J Haematol. 2015 Feb;168(3):361-70. doi: 10.1111/bjh.13138. Epub 2014 Oct 1.
2
Azacitidine in chronic myelomonocytic leukemia: an effective and manageable approach.
Mediterr J Hematol Infect Dis. 2014 Feb 16;6(1):e2014020. doi: 10.4084/MJHID.2014.020. eCollection 2014.
3
Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial.
Blood Cancer J. 2014 Mar 7;4(3):e189. doi: 10.1038/bcj.2014.8.
4
Real-life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile.
Am J Hematol. 2014 May;89(5):565. doi: 10.1002/ajh.23677. Epub 2014 Feb 28.
5
Evolution of chronic myelomonocytic leukemia from refractory anemia: the unusual course of a myelodysplastic syndrome.
Blood Res. 2013 Jun;48(2):152-3. doi: 10.5045/br.2013.48.2.152. Epub 2013 Jun 25.
6
Combination of azacitidine and ESA in myelodysplastic patients: the need for prospective studies.
Leuk Res. 2012 Jun;36(6):682-3. doi: 10.1016/j.leukres.2012.02.020. Epub 2012 Mar 17.
7
Transfusions at home in patients with myelodysplastic syndromes.
Leuk Res. 2012 Jun;36(6):684-8. doi: 10.1016/j.leukres.2012.01.010. Epub 2012 Feb 14.
8
Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?
Leuk Res. 2012 Apr;36(4):397-400. doi: 10.1016/j.leukres.2011.11.019. Epub 2011 Dec 15.
9
Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines.
Leuk Res. 2010 Dec;34(12):1576-88. doi: 10.1016/j.leukres.2010.01.018. Epub 2010 Feb 11.
10
Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome.
Ann Hematol. 2005 Mar;84(3):167-76. doi: 10.1007/s00277-004-0961-9. Epub 2004 Nov 30.
Zotero 插件